华海药业HB0025注射液Ⅲ期临床启动，3亿研发加码多靶点抗癌药领域！

Core Viewpoint - HB0025, an innovative PD-L1/VEGF bispecific fusion protein developed by Huyao Tai, targets tumor immune evasion and angiogenesis, with plans for two confirmatory Phase III clinical trials [3][4]. Group 1: Drug Development Status - HB0025 has shown promising results in Phase II clinical trials for advanced lung squamous cell carcinoma and lung adenocarcinoma, particularly in PD-L1 negative populations, with a good objective response rate (ORR) and low incidence of grade 3 or higher immune-related adverse events (irAEs) [4][8]. - Huyao Tai has invested approximately RMB 325.97 million in the development of HB0025 [8]. Group 2: Competitive Landscape - Competing drugs include KANGFANG BIO's Ivoris monoclonal antibody (PD-1/VEGF dual antibody) which has been approved in China, and BMS's PM8002 and Pfizer's SSGJ-707, both of which are in Phase III clinical trials [4].